BerGenBio ASA is delighted to invite you for COCKTAILS & CANAPES.
This event will include an overview of BerGenBio´s business and Phase II clinical trials updates for its lead product bemcentinib – a potent first-in-class, highly selective, and orally bioavailable small molecule Axl kinase inhibitor as potential cornerstone therapy for cancer. Trials include key combination therapies using immune checkpoint inhibitors (KEYTRUDA), targeted therapies and chemotherapy for NSCLC, AML, TNBC, and melanoma.
- Dr Sonja Loges, Hamburg Eppendorf Medical Center
- Dr David Gerber, UTSW Medical Center
- and more
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy. The Company is a world leader in understanding the essential role of AXL kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive solid and haematological cancers.
BerGenBio’s lead product bemcentinib (BGB324) is a selective, potent and orally bio-available small molecule AXL inhibitor in four Company sponsored Phase II clinical trials in major cancer indications, with read-outs anticipated during 2018. It is the only selective AXL inhibitor in clinical development.
Please RSVP to Priya Nanduri – email@example.com